The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.
Giovanni Scambia
No relevant relationships to disclose
Toby Johnson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Anne Floquet
No relevant relationships to disclose
Florian Heitz
Honoraria - AstraZeneca; Roche
Research Funding - AstraZeneca
Sang-Yoon Park
No relevant relationships to disclose
Martin Buck
No relevant relationships to disclose
Rafael Álvarez Gallego
No relevant relationships to disclose
Muneaki Shimada
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Elisabeth Avall-Lundqvist
No relevant relationships to disclose
Nicoletta Colombo
No relevant relationships to disclose
Anna Maria Mosconi
No relevant relationships to disclose
Bradley J. Monk
Consultant or Advisory Role - GlaxoSmithKline
Jianqing Zhu
No relevant relationships to disclose
Lingying Wu
No relevant relationships to disclose
Ionel Mitrica
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Pingkuan Zhang
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sandy Stinnett
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Chun-fang Xu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Andreas Du Bois
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline